Adagio offers first peek at Covid-19 antibody data, with preventative numbers that may rival mRNA vaccines
Tillman Gerngross certainly wasn’t the first to tackle Covid-19 antibodies, but he has reason to believe he and his team at Adagio could be the best. Now, we’re getting a first peek at human preventative data for Adagio’s lead antibody, and it looks up to par with the best of the vaccines.
Now, Adagio is churning out early data from that Phase I test showing a single dose of antibody ADG20 offered broadly neutralizing activity in healthy volunteers comparable to peak titers reported from the mRNA vaccines and could offer protection for up to 12 months, the biotech said Wednesday. There were no hard numbers immediately available.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.